Suppr超能文献

海洋放线菌:新型生物活性代谢产物的持续来源。

Marine actinomycetes: an ongoing source of novel bioactive metabolites.

机构信息

Centre for Drug Discovery and Conservation, Institute of Applied Sciences, The University of the South Pacific, Laucala Campus, Suva, Fiji.

出版信息

Microbiol Res. 2012 Dec 20;167(10):571-80. doi: 10.1016/j.micres.2012.06.005. Epub 2012 Jul 15.

Abstract

Actinomycetes are virtually unlimited sources of novel compounds with many therapeutic applications and hold a prominent position due to their diversity and proven ability to produce novel bioactive compounds. There are more than 22,000 known microbial secondary metabolites, 70% of which are produced by actinomycetes, 20% from fungi, 7% from Bacillus spp. and 1-2% by other bacteria. Among the actinomycetes, streptomycetes group are considered economically important because out of the approximately more than 10,000 known antibiotics, 50-55% are produced by this genus. The ecological role of actinomycetes in the marine ecosystem is largely neglected and various assumptions meant there was little incentive to isolate marine strains for search and discovery of new drugs. The search for and discovery of rare and new actinomycetes is of significant interest to drug discovery due to a growing need for the development of new and potent therapeutic agents. Modern molecular technologies are adding strength to the target-directed search for detection and isolation of bioactive actinomycetes, and continued development of improved cultivation methods and molecular technologies for accessing the marine environment promises to provide access to this significant new source of chemical diversity with novel/rare actinomycetes including new species of previously reported actinomycetes.

摘要

放线菌是具有多种治疗应用的新型化合物的几乎无限来源,由于其多样性和生产新型生物活性化合物的能力已得到证实,因此占有突出地位。已知有超过 22000 种微生物次生代谢产物,其中 70%由放线菌产生,20%由真菌产生,7%由芽孢杆菌属产生,其余 1-2%由其他细菌产生。在放线菌中,链霉菌属被认为具有重要的经济意义,因为在已知的大约 10000 多种抗生素中,有 50-55%是由该属产生的。海洋生态系统中放线菌的生态作用在很大程度上被忽视了,各种假设意味着没有什么动力去分离海洋菌株来寻找和发现新的药物。由于人们对开发新型有效治疗剂的需求不断增长,因此稀有放线菌的寻找和发现对于药物发现具有重要意义。现代分子技术为有针对性地寻找和分离具有生物活性的放线菌提供了更强的支持,不断改进的培养方法和分子技术的发展,有望为开发这一具有新型/稀有放线菌的重要新化学多样性来源提供途径,包括以前报道过的放线菌的新物种。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验